SILS to receive ~15 per cent stake in BBL at a post-money valuation of ~$4.9 billion
Biocon Biologics Limited (BBL), a subsidiary of Biocon and Serum Institute Life Sciences (SILS), a subsidiary of Serum Institute of India announced a strategic alliance. Under the terms of the agreement, BBL will offer approximately 15 per cent stake to SILS, at a post-money valuation of ~$4.9 billion, for which it will get committed access to 100 million doses of vaccines per annum for 15 years, primarily from SILS’s upcoming vaccine facility in Pune with commercialization rights of the SILS vaccine portfolio (including COVID-19 vaccines) for global markets.
Under the terms of the agreement, BBL will generate a committed revenue stream and related margins, commencing H2, FY23. Adar Poonawalla will have a Board seat in BBL.
In addition to vaccines, the strategic alliance will also develop antibodies targeting several infectious diseases like Dengue, HIV, etc. The two companies will enter Service Level Agreements (SLAs) for manufacturing and distribution of the vaccines and antibodies.
Vaccines are a complementary business fit to BBL and provide a new dimension to its effort in improving global healthcare. Most recently, BBL announced a manufacturing and commercialization partnership in select emerging markets with Boston-based Adagio Therapeutics for ADG20, a novel COVID-19 antibody therapy. These collaborations support Biocon Biologics’ intent of straddling on both infectious and non-communicable diseases in its quest to impact global health.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics, said, “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics. Our shared vision of building large scale businesses having global impact makes it a unique and synergistic value creation opportunity.”
Adar Poonawalla, CEO, Serum Institute of India, commented, “We look forward to complementing each other’s capabilities and capacities in vaccines and biologics, to address inequitable access both in emerging and developed markets for life-saving vaccines and biologics.”
